drugset
drugset / Trial / NCT02809690

18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer

NCT02809690 ↗

Phase 1 Terminated 18 enrolled University of Southern California National Cancer Institute (NCI) · collabNational Institute for Biomedical Imaging and Bioengineering (NIBIB) · collab
NaSingle-groupOpen-labelDiagnostic

Summary

This pilot clinical trial studies how well fluorine F 18 d-FMAU (18F-FMAU) positron emission tomography (PET)/computed tomography (CT) works in diagnosing and characterizing prostate cancer. A PET/CT scan is an imaging test that uses a small amount of radioactive tracer that is given through the vein to take detailed pictures of areas inside the body where the tracer is taken up. Radiotracers such as 18F-FMAU may help to find the cancer and see how far the disease has spread.

Timeline

Start
2016-09-12
Primary completion
2021-07-21
Completion
2021-07-21

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FMAU Diagnostic / imaging agent — Intravenous

Indications

prostate neoplasm